Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Expedition Growth Capital in connection with its investment in Factbird
Mandate

Vinge advises Expedition Growth Capital in connection with its investment in Factbird 

November 27, 2023 M&A

Expedition Growth Capital, together with the Export and Investment Fund of Denmark (EIFO), have completed its investment in the Danish tech company Factbird. Vinge acted for Expedition Growth Capital in connection with the investment.

Factbird, which has been in rapid growth since 2021, supplies 250+ customers with intelligent, cloud-based technology for the optimization of manufacturers production lines. Expedition Growth Capital is a London-based growth equity fund focused on investing in fast-growing companies still in their start-up phase.

Vinge’s team consisted of Karl Klackenberg and Per Kling.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026